42182-27-4

Basic information

• Product Name: 2-Amino-4-cyanopyridine
• Synonyms: 4-PYRIDINECARBONITRILE, 2-AMINO-;2-AMINO-4-CYANOPYRIDINE;2-Aminoisonicotinonitrile;4-Cyano-2-pyridinamine;5-AMINO-4-CYANOPYRIDINE;2-Amino-4-pyridinecarbonitrile;2-aminopyridine-4-carbonitrile;2-Amino-4-cyanopyrid
• CAS NO: 42182-27-4
• Molecular Formula: C₆H₅N₃
• Molecular Weight: 119.12
• EINECS: -0
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;pharmacetical;Pyridine series;Chemical Amines;Pyridine;Amines;Heterocycles;Pyridines;Heterocycle-Pyridine series
• Mol File: 42182-27-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 146-148°C
• Boiling Point: 297.7 °C at 760 mmHg
• Flash Point: 133.8 °C
• Appearance: /
• Density: 1.23 g/cm³
• Vapor Pressure: 0.00133mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.93±0.11(Predicted)
• Water Solubility: Slightly soluble in water.
• BRN: 386393
• CAS DataBase Reference: 2-Amino-4-cyanopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-cyanopyridine(42182-27-4)
• EPA Substance Registry System: 2-Amino-4-cyanopyridine(42182-27-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-41-37/38-22
• Safety Statements: 26-36/37/39-36-39
• RIDADR: 3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 42182-27-4(Hazardous Substances Data)

Usage

Description

2-Amino-4-cyanopyridine is a pyridine derivative characterized by its yellow or pale brown crystalline powder form. It is a compound with significant pharmaceutical relevance due to its properties as a mGluR2 antagonist.

Uses

Used in Pharmaceutical Industry:
2-Amino-4-cyanopyridine is used as a mGluR2 antagonist for the treatment of central nervous system (CNS) disorders. Its application is based on its ability to modulate the activity of the metabotropic glutamate receptor 2 (mGluR2), which plays a crucial role in various neurological processes and has been implicated in the pathophysiology of several CNS disorders.
Used in Research and Development:
2-Amino-4-cyanopyridine is also utilized in the research and development of novel therapeutics targeting the mGluR2 receptor. Its use in this context is due to its potential to provide insights into the receptor's function and contribute to the development of new drugs for the treatment of CNS disorders.

InChI:InChI=1/C6H5N3/c7-4-5-1-2-9-6(8)3-5/h1-3H,(H2,8,9)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 557-21-1 dicyanozinc 
• 557-21-1 zinc(II) cyanide 
• 84249-14-9 2-amino-4-bromopyridine 
• 737000-78-1 tert-butyl (4-cyanopyridin-2-yl)carbamate 
• 504-29-0 2-aminopyridine 
• 552331-00-7 4-(iodo)pyridin-2-amine 
• 33252-30-1 2-chloro-4-pyridinenitrile 

Downstream Products

• 199296-51-0 2-amino-4-aminomethylpyridine 
• 1356000-01-5 {1-[4-(7-cyano-3-phenyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-cyclobutyl}-carbamic acid tert-butyl ester 
• 1393106-21-2 2-amino-5-chloro-4-cyanopyridine 
• 1496581-76-0 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile 
• 1608144-25-7 2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)furo[2,3-b]pyridin-2-yl)propane-1,3-diol 
• 94805-51-3 2-hydroxyisonicotinonitrile 
• 1608146-70-8 5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-3-iodopyridin-2-ol 
• 1608146-72-0 tert-butyl N-(5-{5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]furo[2,3-b]pyridin-2-yl}-2,2-dimethyl-1,3-dioxan-5-yl)carbamate 
• 1620677-19-1 4-bromo-N-(4-cyanopyridin-2-yl)-3-fluorobenzamide 
• 1620677-18-0 N-(4-cyanopyridin-2-yl)-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1620677-22-6 N-(4-cyanopyridin-2-yl)-3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1620677-23-7 4-bromo-N-(4-cyanopyridin-2-yl)-3-methoxybenzamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

ORGANIC COMPOUNDS

Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans